Last edition
News about "China NMPA approval"
Milestone's Etripamil Nasal Spray Wins China NMPA Approval for PSVT
Milestone Pharmaceuticals’ etripamil nasal spray receives China NMPA approval for PSVT, triggering a USD 2 million payment and expanding access in Greater China.
China NMPA Approval | 05/09/2026 | By News Bureau
China Accepts Bayer's Aflibercept 8 mg Application for RVO Macular Edema Review
China’s National Medical Products Administration (NMPA) accepts aflibercept 8 mg for review in RVO-related macular edema, supported by positive Phase 3 QUASAR results.
China NMPA Approval | 14/08/2026 | By News Bureau | 114
Enhertu Plus Pertuzumab Approved in China for First-Line HER2-Positive Metastatic Breast Cancer
Enhertu plus pertuzumab has been approved in China as first-line treatment for HER2-positive metastatic breast cancer, based on positive phase 3 results.
China NMPA Approval | 13/08/2026 | By News Bureau | 108
Zai Lab Secures China Approval for TIVDAK
Zai Lab has received China NMPA approval for TIVDAK (tisotumab vedotin), the first Antibody-Drug Conjugate (ADC) approved for previously treated recurrent or metastatic cervical cancer in China. The approval is supported by phase 3 innovaTV 301 trial data demonstrating a statistically significant overall survival benefit.
China NMPA Approval | 09/06/2026 | By News Bureau | 207
Lupin Secures China Approval for Oseltamivir Phosphate Oral Suspension
Lupin receives approval in China for Oseltamivir Phosphate Oral Suspension 6 mg/mL, expanding access to influenza treatment, particularly for pediatric patients.
China NMPA Approval | 25/05/2026 | By News Bureau | 158
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy